1. Corporate social responsibilities
Genzyme’s CSR dilemma: How to PLAY ITS HAND
Genzyme,isone of the globallyleadingbiotechnologyfirm, the uniquenessof Genzymeis, when
comparedto theirrivalry,they emphasismore andworkonneglecteddieses. Seniorvice presidentof
Genzyme Mr. JimGeraghty,hascreatedthe HumanitarianAssistance forNeglectedDiseases(HAND).
Genzyme has earliersupportedandprovidedadvancedtreatmentforneglecteddiseases like Malaria,
Chagas andsleepingsickness.Afterskeptical fearIcame to a suggestion thatitwouldbe sensible,under
fewlimitationstotrackall the three advantagesandsynchronize toshow Genzyme’sfullobligationto
Corporate Social Responsibility.
1) The Chagas Project: We can see fromthe add-ons,Cerezymeisearningalotof turnover.In2008
$100M profitwasgeneratingfromBraziliangovernment,Genzyme hadinfluenced tothe governmentof
Brazil that HANDprogram reinforcedthe cure of Gaucher,and Brazil governmentwasrevising itasan
exceptionaldrugsbyhavingone single patron.The Chagasgrowthisrespected asthe honestgivebackto
Brazil as CSR profile builtoveryears
2) The Malaria Initiative:AfterexploringIndia, itisimportanttobuild potential partnerships withchain
forcesin structure programs forneglecteddiseases.Malariaiswide-rangingrange inIndia,they
expected withindustryexpertonMalaria andvaccines fromICGEB seemedcapable andGenzymeisstill
a start-uplookingforreliable partnerstoposition. TargetingonlyonMalariaand specificdiesescan
buildanimage of common R&D performer.
3) The Tuberculosisoption:It has a huge demandand attentionbecause itisavast global health
concern.Whencomparedto malaria,TB isnot enticingimportantpropertiesandtechnological
properties,still ithashighesthumanityratesgloballyforneglecteddisease.Because of existingallied
withscientistatHBR a possible newvaccine canbe developedunderHANDinitiative.
Recommendation:All the three advantages willbringbenefittooverall HANDedges.Asthe Chagas
initiativewillearnback,Malariainitiativewillbe successful bypartnershipandthe TB optionisfully
remindyouof HAND standsforwhichpurpose. Neglecteddisease are massiverange amidthe lowliest
populationinthe world,whichincludesmanyemergingareasAfrica,AsiaandSouthAmerica.Asper
WHO ignoreddiseasesmostlyimpactpeople inrural areasof the countries. ExpandinginBRICswill
certainlymakesapositive influence onsociety andif Genzyme successfullycreatesnew drugforMalaria
and TB. ExistingdrugCerezyme raise Genzyme tonextlevel because itwaslistedinunique medicinesfor
uncommondiseasesandguaranteedthatthe firmwill get reimbursementfromBrazil government.On
the otherhand partnershipwithICGEBwhichcreateda new Vaccinesformalaria wouldbuildreputation
of Genzyme asCSR organization.Asadecision we cansayboth the advantagesdoesnotdifferfromone
anotheras inIndiaand Brazil the firmhas same strategyof cooperationwithgovernmentasthese
initiativesare sociallyaccountable andaimforhealthypopulation
Pro's Con's Pro's Con's Pro's Con's
Protecting revenues Evoke demand to outroll Big market Evolving differnet agenda Worldwide growth No partnership
Phase2, vaccine on hand Downward effect in CSR
Vaccine can be
transmitted to Brazil
Intial risk
Successful relations
with Scientist in US
Require more
technology
Chagas project Malaria Tuberclosis